Wled Wazni, MD
Vascular Neurology · Long Beach, CANPI 1528297009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Johnson & Johnson at 34.1% of the total. Reporting peaked in 2022 at $3,238 and has fallen 74.9% since, to $814 in 2025.
Across 276 payments — averaging $39.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Stryker$2K
- Medtronic$2K
- Penumbra, Inc.$894
- Microvention, Inc.$290
- Imperative Care, Inc$282
- plus $1K from 15 others
What the payments were for
- Food & beverage$10,77399%
- Education$801%
- Gifts$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 130 | $3,702 |
| Stryker | 44 | $2,463 |
| Medtronic(2 entities) | 56 | $2,226 |
| Penumbra, Inc. | 15 | $894 |
| Microvention, Inc. | 5 | $290 |
| Imperative Care, Inc | 5 | $282 |
| Route 92 Medical, Inc. | 1 | $188 |
| Balt USA, LLC | 2 | $182 |
| Medical Device Business Services, Inc. | 5 | $156 |
| AstraZeneca | 1 | $80 |
| Scientia Vascular | 1 | $54 |
| Boston Scientific | 1 | $45 |
| Siemens Medical Solutions USA, Inc. | 1 | $44 |
| Portola Pharmaceuticals, LLC | 1 | $44 |
| Philips North America LLC | 1 | $43 |
| Cordis US CORP. | 1 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Lundbeck LLC | 1 | $30 |
| Abbott | 1 | $27 |
| GE HealthCare | 1 | $17 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Embotrap$910
- TREVO$545
- Pipeline$484
- SURPASS EVOLVE$376
- TRUFILL$312
- SOLITAIRE X$292
- Penumbra System$271
- STENT$232
- WEB Aneurysm Embolization System$232
- EMBOGUARD$188
- CEREPAK UNIFORM$149
- N/A$144
- Optima Coil System$138
- ZOOM 88-T LARGE DISTAL PLATFORM$133
- HYDROSOFT ADVANCED$126
- Penumbra Jet 7$123
- TARGET$121
- Galaxy G3$117
- Solitaire$111
- Jet 7$109
How this compares
$10,857 in reported general payments places this provider in the 75th percentile of 58 vascular neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 21 | $8,978 |
| Ergotamine-CaffeineErgotamine Tartrate/Caffeine | 13 | $5,661 |
| Lacosamide | 25 | $1,620 |
| Carbamazepine ErCarbamazepine | 11 | $1,263 |
| Levetiracetam | 36 | $613 |
| Phenytoin Sodium Extended | 20 | $492 |
| ClopidogrelClopidogrel Bisulfate | 13 | $143 |
| Divalproex Sodium | 13 | $121 |
| Atorvastatin Calcium | 17 | $105 |
| Topiramate | 28 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $80 | $8,97821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 58 vascular neurology providers in California.
Other vascular neurology in Long Beach
- Banafsheh YafehLong Beach$17K
- Gregory AlbersStanford$415K
- Chitra VenkatasubramanianStanford$260K
- Shuichi SuzukiArcadia$126K
- Royya ModirSan Diego$113K
- Maarten LansbergStanford$86K
- Muhammad TaqiPalm Springs$77K
- Ashish NandaFullerton$66K
- Andrew XavierMountain View$46K
- Sarah LeeStanford$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.